Biontech, Moderna and the other vaccine manufacturers have started the fight against the new virus variant Omikron.
A look at the share prices alone reveals that this promises to be good business again.
In this podcast, Eva Müller, expert at manager magazin für Biotech, in an interview with editor-in-chief Martin Noé, provides information on where the individual manufacturers stand, how long production would take and what the future of vaccination could look like.
In the podcast "The Topic" the editor-in-chief of manager magazin provides information every Friday about the research status on a relevant current and at the same time promising topic of the economy. You can subscribe to the podcast via manager magazin as well as on Spotify, Apple, Deezer and on google.
